# Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

> **NCT03037437** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 64 (actual)

## Conditions studied

- Hepatocellular Cancer

## Interventions

- **DRUG:** Sorafenib (SOR)
- **DRUG:** Hydroxychloroquine (HCQ)

## Key facts

- **NCT ID:** NCT03037437
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-16
- **Primary completion:** 2025-06-27
- **Final completion:** 2025-06-27
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03037437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03037437, "Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03037437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*